An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy (Q44371735)

2 December 2017

title

An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy (English)

1 reference

2 December 2017

1 reference

B Abou-Khalil

1 reference

2 December 2017

Paula Hemdal

series ordinal

1 reference

2 December 2017

M D Privitera

series ordinal

1 reference

2 December 2017

publication date

1 April 2003

1 reference

Seizure-European Journal of Epilepsy

2 December 2017

published in

1 reference

2 December 2017

1 reference

2 December 2017

1 reference

2 December 2017

page(s)

141-149

1 reference

Pharmacokinetic profile of levetiracetam: toward ideal characteristics

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

The new generation of antiepileptic drugs: advantages and disadvantages

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

ucb L059, a novel anti-convulsant drug: pharmacological profile in animals

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Tolerability and pharmacokinetics of monotherapy felbamate doses of 1,200-6,000 mg/day in subjects with epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Long-term continuation of levetiracetam in patients with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1059-1311%2802%2900292-3

7 January 2021

10.1016/S1059-1311(02)00292-3

Identifiers

DOI

1 reference

2 December 2017

1 reference